Company Analysis Kymera Therapeutics, Inc.
1. Summary
Advantages
- The stock's return over the last year (36.71%) is higher than the sector average (-49.04%).
- Current debt level 8.97% is below 100% and has decreased over 5 years from 18.17%.
Disadvantages
- Price (63.53 $) is higher than fair price (55.53 $)
- Dividends (0%) are below the sector average (0.5339%).
- The company's current efficiency (ROE=-36.38%) is lower than the sector average (ROE=103.63%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Kymera Therapeutics, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 4.1% | -35.1% | 0.1% |
| 90 days | 49% | -48% | 6.7% |
| 1 year | 36.7% | -49% | 17.9% |
KYMR vs Sector: Kymera Therapeutics, Inc. has outperformed the "Healthcare" sector by 85.75% over the past year.
KYMR vs Market: Kymera Therapeutics, Inc. has outperformed the market by 18.81% over the past year.
Stable price: KYMR is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: KYMR with weekly volatility of 0.706% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Above fair price: The current price (63.53 $) is higher than the fair price (55.53 $).
Price is higher than fair: The current price (63.53 $) is 12.6% higher than the fair price.
5.2. P/E
P/E vs Sector: The company's P/E (-13.36) is higher than that of the sector as a whole (-274.25).
P/E vs Market: The company's P/E (-13.36) is higher than that of the market as a whole (-80.5).
5.3. P/BV
P/BV vs Sector: The company's P/BV (3.61) is lower than that of the sector as a whole (256.7).
P/BV vs Market: The company's P/BV (3.61) is lower than that of the market as a whole (51.89).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (64.14) is higher than that of the sector as a whole (56.99).
P/S vs Market: The company's P/S indicator (64.14) is lower than that of the market as a whole (137.42).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-13.81) is lower than that of the sector as a whole (12.51).
EV/Ebitda vs Market: The company's EV/Ebitda (-13.81) is higher than that of the market as a whole (-47.95).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Rising and has grown by 82.22% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (82.22%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-22.73%).
6.4. ROE
ROE vs Sector: The company's ROE (-36.38%) is lower than that of the sector as a whole (103.63%).
ROE vs Market: The company's ROE (-36.38%) is lower than that of the market as a whole (-10.25%).
6.6. ROA
ROA vs Sector: The company's ROA (-28.81%) is lower than that of the sector as a whole (-2.84%).
ROA vs Market: The company's ROA (-28.81%) is lower than that of the market as a whole (39.65%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (-33.64%) is lower than that of the sector as a whole (1.17%).
ROIC vs Market: The company's ROIC (-33.64%) is lower than that of the market as a whole (8.73%).
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5339%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
9. Insider trades
9.1. Insider trading
Insider Selling More insider purchases by 101.33% over the last 3 months.
9.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 10.12.2025 | Atlas Venture Fund X, L.P. Director |
Purchase | 89.89 | 1 735 | 193 040 |
| 10.12.2025 | Atlas Venture Opportunity Fund Director |
Purchase | 89.89 | 331 | 36 769 |
| 08.12.2025 | Mainolfi Nello Officer |
Purchase | 89.17 | 892 | 100 000 |
| 08.12.2025 | Gollob Jared Chief Medical Officer |
Sale | 88.67 | 437 | 49 307 |
| 08.12.2025 | Gollob Jared Chief Medical Officer |
Purchase | 5.33 | 26 281 | 49 307 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
Based on sources: porti.ru
